Inogen (INGN)
Nasdaq Market Closed
Inogen is a medical technology company focused on respiratory care, best known for its portable oxygen concentrators. Its products are designed for patients who require supplemental oxygen therapy, including people living with chronic respiratory conditions such as chronic obstructive pulmonary disease. By concentrating oxygen from ambient air, these devices offer an alternative to traditional oxygen tanks and support greater mobility for eligible patients.
The company develops, manufactures, markets, sells, and rents respiratory products. Its portable oxygen concentrator portfolio is central to the business and is aimed at helping patients receive long-term oxygen therapy in a form that can be used at home or while travelling. Inogen also offers broader respiratory health products, including the Simeox airway clearance system, the Inogen Voxi 5 stationary oxygen concentrator, and Aurora continuous positive airway pressure masks in the United States.
Inogen sells through multiple channels, including direct-to-consumer activity, business-to-business relationships, and rental arrangements. This model exposes the company to consumer demand, physician and provider recommendations, reimbursement rules, and durable medical equipment distribution practices. Because oxygen therapy is a regulated area of healthcare, product quality, service, documentation, and payer requirements are important parts of the business.
The company operates in a market shaped by ageing populations, chronic lung disease, hospital-to-home care trends, and the desire for devices that are smaller, lighter, and easier to use. Inogen’s distinguishing position is its long-standing emphasis on portable oxygen technology and patient mobility, supported by a broader respiratory product line that extends its relevance across home-based respiratory care.
Last updated
- Market Cap
- 161.91M
- P/E
- —
- P/FCF
- —
- P/S
- 0.46
- Enterprise Value
- 68.79M
- Sector
- Health Care
- Industry
- Orthopedic, Prosthetic, and Surgical Appliances and Supplies
- Address
- 500 CUMMINGS CENTER, BEVERLY, MA, 01915
Global Oxygen Therapy Equipment Market is Predicted to Surge at ~8% CAGR by 2032 Owing to the Rising Respiratory Disorders and Technological Advancements | DelveInsight
US Durable Medical Equipment Market Forecast and Competitive Landscape Report 2025-2033 | Invacare, NOVA, Inogen, Thermo Fisher Scientific, Abbott, Medtronic, Baxter, B. Braun, Boston Scientific, BD
Tosyalı lance l'un des plus grands projets de centrale solaire en autoconsommation au monde
Tosyalı Launches one of the World’s Largest Self-Consumption Solar Power Plant Projects
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now - Zacks Investment Research
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y
Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings
Will These 5 Medical Device Stocks Beat This Earnings Season?
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue?
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
Gear Up for Inogen (INGN) Q4 Earnings: Wall Street Estimates for Key Metrics
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 161.91M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 68.79M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.89
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.46
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -5.98
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 0.2
- EPS
- -0.92
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -2.38M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -13.61%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -8.71%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 3.08
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.68
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.52
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 370.78K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 5.98
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 85.11M | 81.72M | 92.39M | 92.28M | 82.28M |
| Gross profit | 37.86M | 35.24M | 41.32M | 41.34M | 36.37M |
| Operating income | -9.34M | -9.31M | -7.12M | -6.13M | -7.66M |
| EBITDA | -4.43M | -4.27M | -1.9M | -913K | -2.47M |
| Net income | -8.32M | -7.13M | -5.29M | -4.15M | -6.17M |
| Basic EPS | -0.3 | -0.27 | -0.2 | -0.15 | -0.25 |
| Diluted EPS | -0.3 | -0.27 | -0.2 | -0.15 | -0.25 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 285.93M | 298.63M | 307.01M | 312.04M | 308.41M |
| Total liabilities | 103.02M | 106.39M | 109.83M | 112.55M | 110.46M |
| Total equity | 182.91M | 192.23M | 197.18M | 199.49M | 197.95M |
| Cash & equivalents | 93.11M | 103.73M | 106.48M | 103.69M | 118.89M |
| Current assets | 189.37M | 197.01M | 202.43M | 201.85M | 197.06M |
| Current liabilities | 61.45M | 63.54M | 64.94M | 67.07M | 65.45M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -6.69M | -943K | 2.17M | 4.35M | -16.79M |
| Investing cash flow | -1.98M | -1.52M | -82K | -22.57M | -2.04M |
| Financing cash flow | -2.12M | -187K | 418K | 0 | 23.95M |
| Change in cash | -10.61M | -2.74M | 2.8M | -17.58M | 5.12M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Inogen Inc | View Filing | |
| edgar index | 144 — Inogen Inc | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| edgar index | SD — Inogen Inc | View Filing | |
| edgar index | 10-Q — Inogen Inc | View Filing | |
| edgar index | 8-K — Inogen Inc | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-8 — Inogen Inc | View Filing | |
| edgar index | DEF 14A — Inogen Inc | View Filing | |
| edgar index | ARS — Inogen Inc | View Filing | |
| edgar index | PRE 14A — Inogen Inc | View Filing | |
| edgar index | 3 — Inogen Inc | View Filing | |
| edgar index | 4 — Inogen Inc | View Filing | |
| edgar index | 8-K — Inogen Inc | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Richardson Jason Andrew | View Filing | |
| edgar index | 8-K — Inogen Inc | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Inogen Inc | View Filing | |
| edgar index | 4 — Inogen Inc | View Filing | |
| edgar index | 4 — Inogen Inc | View Filing | |
| edgar index | 4 — Inogen Inc | View Filing | |
| edgar index | 4 — Inogen Inc | View Filing | |
| edgar index | 4 — Inogen Inc | View Filing | |
| edgar index | 4 — Inogen Inc | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Smith Kevin Raymond Merrill | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Bourque Michael J. | View Filing | |
| form 4 | Form 4 — Smith Kevin P. | View Filing | |
| form 4 | Form 4 — Smith Kevin P. | View Filing | |
| form 4 | Form 4 — Smith Kevin P. | View Filing | |
| form 4 | Form 4 — Smith Kevin P. | View Filing | |
| form 4 | Form 4 — Ramade Gregoire | View Filing | |
| form 4 | Form 4 — Ramade Gregoire | View Filing | |
| form 4 | Form 4 — Ramade Gregoire | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Yi Boyer Jennifer M | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| form 4 | Form 4 — Wright Mary E | View Filing | |
| edgar index | 10-K — Inogen Inc | View Filing | |
| edgar index | S-8 — Inogen Inc | View Filing |